> Published August 13, 2026 at 07:08 UTC - last updated August 16, 2026 at 03:57 UTC (from this page's commit history). > > Markdown mirror of https://colorado-medical-cannabis.org/developing-stories/science-policy-forum/2025-08-01/ > > Everything up to "Appendix for agents" is the page as a reader sees > it. The HTML page is a subset of this file, rewritten for human > readability. > > The appendix is context that does not appear on the page. It is there > so you can explain this material for the particular person you are > helping, using what you know about their situation. It is background > for you, not text to hand them. # The August 1, 2025 forum: flower labels fail a statewide test, and the surveillance program takes shape
**Being researched:** this page reports our research in progress. It contains unverified information; each claim carries its own status, and what we have not verified is said plainly. Published and updated times come from this page's commit history.
Colorado's Science & Policy Forum met August 1, 2025, five months before the new testing rules took effect. We transcribed the Division's published recording (about 96 minutes) with a speech-recognition model and drafted this summary from that transcript; our editor has reviewed and approved this page, and the recording remains the source of record. The published recording begins mid-session: the meeting was disrupted and restarted in a locked-down webinar format, with the co-chairs apologizing on the record for "grossly offensive and inappropriate language and images" at the start and moving all participation to moderated Q&A [0:00:00, 1:30:52]. What the recording preserves is the substance. And the substance was two of the biggest threads of the coming year. ## Notes from the editor First, something the public should sit with: the conditions the state asks its own scientists to work in. The people running the state's surveillance tests are highly trained chemists and technicians, and Colorado houses them in a 30-year-old building whose air handlers failed one after another over the winter ([one exploded](../2026-01-09/)) and where metals testing went down entirely for lack of exhaust ventilation. In a chemistry lab, that ventilation is what stands between the people working there and the solvents and toxins they handle. And this is not an abstract facilities story: what the building's failures have delayed is **health and safety testing**. Every product on a shelf passed a lab test before it was packaged. But mold grows between packaging and sale, mites and pests can get in, and a mishandled or badly made package can let in anything. Shelf surveillance is the only testing that looks at a product the way a customer actually receives it. The Division defended the program on exactly that ground at this meeting. Is post-packaging contamination a big health problem? Probably not. But nobody knows, because the checks that would tell us haven't run. And things you don't know can hurt you. Keep the scale in mind, too. This testing system consumes real money and many hours of very talented scientists' and technicians' time. Spending that efficiently matters. And to their credit, the regulators in these recordings are visibly trying to. But remember who actually pays for all of it: you. The cost of every required test lands in the shelf price, and the state collects its cannabis taxes on top. People who hand the state that money deserve a state that provides adequate scientific facilities in return. That is part of what makes it safe to give the state your money. When flower surveillance slips a year, the easy move is to blame the lab. Blame the building. A state that wants trustworthy cannabis testing has to fund the facility, not just the mandate. Now, here's the situation this meeting put on the record. An independent researcher (the holder of Colorado's only marijuana research-and-development license) bought 281 products off dispensary shelves across the state and had them tested against their own labels. The study was run *blinded*: the lab tested each sample without knowing what its label claimed, while a University of Colorado team held the key matching samples to products. That design matters: a lab that can't see the label can't be tempted, even unconsciously, to nudge a number toward it. The study was presented to the state's own science forum, in public, in August 2025. No one at the meeting, regulator or industry, disputed its findings: that concentrate labels were honest about 96% of the time, and that flower labels were wrong more than half the time, mostly claiming more THC than was in the jar. The question a reader should ask first about this meeting is the one I asked: **did the state change how flower is tested as a result of these findings?** The answer, a year later, is no. The [January 5, 2026 rules](../../marijuana-testing-overhaul/what-changed/) left the strain-based flower potency schedule (the structural cause the Division's own co-chair identified at this meeting) in place, and the state's own check of flower labels has still never run. The study's quieter finding aged into the bigger story. CBG (cannabigerol) is the plant's starter cannabinoid, the raw material it converts into THC and CBD as it matures. It's biologically active and barely studied in humans. The study found it in nearly every concentrate, sometimes near 4%: a real dose of a compound that wasn't on the label. The concern isn't that CBG is known to be harmful; it's that people were taking it without being told, in amounts nobody was tracking. That unlabeled-minor-cannabinoid sighting was an early glimpse of what the Division's science director confirmed on the record in [June 2026](../2026-06-12/): hemp-derived cannabinoids, intentionally added, now riding at ratios that rival THC. Be careful to split that in two. Adding hemp-derived cannabinoids to a product is arguably a legitimate formulation choice, provided the hemp gets safety testing, which the January 5 rules now require for any hemp entering the regulated market. Converting hemp CBD into intoxicating cannabinoids with solvent chemistry is a different animal entirely: uncontrolled synthesis that leaves behind byproducts the standard test panel was never designed to see. The state agrees: it wrote a dedicated conversion-solvent screen into the January 5 rules. That screen has been law for seven months and has never run, because no lab in the state is certified to perform it. Until it runs, the legitimate path and the bad one walk through the same door, indistinguishable. ## Since this meeting *Where the threads this meeting opened stand as of August 2026, from the year of recordings that followed.* **Resolved.** The surveillance program presented here as a draft became real: its design was locked at the [September 2025 meeting](../2025-09-12/), it launched on schedule, and its edibles phase was executed and [publicly reported in June 2026](../2026-06-12/): every safety test passed; only 47% of samples matched their label on both potency and homogeneity. **Still in progress.** The label-wording chaos this study documented (THC, total THC, THCA; even the academic team had to guess) is finally the target of rulemaking: standardized reporting units and labeled-cannabinoid testing requirements were [previewed in July 2026](../2026-07-10/) for the August rulemaking season. Proposals, not yet law, and driven by the edibles surveillance data, because that's the only data the state has produced. **Put off or neglected.** Flower, the headline of this meeting. The category this study said fails more than half the time is the one category the state has never retested: flower surveillance slipped from early 2026 to [fall 2026](../2026-04-03/) behind test-method validation and physical breakdowns at the state lab's 30-year-old building: its air-handling units failed, [one explosively](../2026-01-09/), taking the safety ventilation a chemistry lab can't run without offline for weeks. No rule change has touched how flower potency is tested or labeled. And where the state *does* have retest data (edibles), the question this study opened was put to the forum directly at the [August 7, 2026 meeting](../../marijuana-testing-overhaul/august-7-forum/) and answered with "I don't think we have an answer to that." The who-pays-for-samples question posed here was never settled. And the presenter's 30%-THC skepticism was not returned to in any later recording we transcribed. ## What was brought up **A statewide test of whether labels tell the truth** [0:05:04]. The holder of Colorado's only marijuana research-and-development license (a researcher with an ISO-certified analytical lab, working blinded with a University of Colorado Boulder team) presented a published study that purchased 281 products from 52 recreational dispensaries across the state and compared the label to what the lab measured. The headline findings as presented: **concentrates were honest** (about 96% matched their label within a ±15% variance) while **flower failed more than half the time**, with roughly 56–57% of flower products outside the variance band, most of them labeled higher than they measured, some lower, with a wide spread in both directions [0:10:08]. Secondary findings: CBG turned up in nearly all concentrates, sometimes near 4% (an unlabeled, arguably meaningful dose of a little-studied cannabinoid) [0:50:30], and label wording was chaotic enough (THC, total THC, THCA) that even the study's own academic team had to guess what some labels claimed [0:20:11]. **Why flower fails and concentrates don't** [0:25:14]. The Division's co-chair connected the result to the rules themselves: every concentrate batch must be potency-tested, while flower potency rides on a strain-based schedule (the first four harvests, then quarterly), so a label can describe a test months removed from the jar it's on. The presenter added the physics: concentrates are homogeneous by manufacture; flower is a living plant that varies plant to plant and dries season to season. **The surveillance program's working design** [1:05:35]. The Division walked through its draft shelf-surveillance program: roughly 150 samples over three months, one product category per month (edibles, then concentrates and infused pre-rolls, then flower and pre-rolls), producers selected by a market-share-weighted stratified draw, samples collected from store shelves by MED investigators "prepared just like they were serving a customer" [1:20:46, 1:25:50]. A staff physical scientist presented the collection SOPs: sanitized coolers, temperature and humidity data loggers, evidence-bag chain of custody, same-day courier delivery to the reference lab where possible [1:20:46]. ## What was nailed down - **The study's design points, as presented**: 281 products, 52 stores, purchases spread statewide under daily limits, whole-sample homogenization including stems, blinded analysis with the academic team holding the key, results published in a peer-reviewed journal [0:05:04–0:20:11]. - **The surveillance program's structure**: category-per-month sequencing, stratified market-share sampling, store-level substitution rules, and draft collection SOPs shared for stakeholder review, with a September launch target [1:30:52]. - **Health-and-safety advisories stay case-by-case**: a failed surveillance test triggers the existing MED–CDPHE consultation process, not an automatic advisory [1:05:35]. - **The format change**: after the disruption, the forum moved to webinar mode with moderated Q&A, "to control access" [0:00:00]. ## What was left open - **Whether surveillance should duplicate what the study already showed.** The Division openly asked whether concentrate potency testing should be dropped from the surveillance program, since the published data showed concentrate labels largely honest: a resource-versus-redundancy question left for the September meeting [1:05:35]. - **Who pays for the samples.** Surveillance samples are taken from store shelves without payment; whether cultivators and manufacturers would backfill stores' losses was posed as a question licensees should settle among themselves. Unresolved [1:10:38]. - **Where sampling should happen.** A commenter argued samples should come from grows and manufacturers before market entry, not from sales floors; the Division defended shelf sampling as the only way to see what actually reaches consumers, including transport and storage effects [1:15:44]. - **How to fix flower labeling.** The presenter's view: tighten label verbiage rules and testing-lab practices before rebuilding the whole system: "there are tweaks that you can make... without blowing up the entire system" [0:55:31]. The underlying question (whether flower potency labeling can be accurate at all under strain-based testing) was named but not answered. - **What 30%+ THC flower labels mean.** The presenter's skepticism, as a biologist: chlorophyll is the plant's most abundant compound at around 30%: "to have this many products testing that high begs the question of how we're getting there" [0:40:23]. *This summary was drafted by our AI desk from a machine transcript and has been reviewed and approved by our editor (2026-08-12). The research findings described are the presenter's published claims as stated at the meeting. This site has not independently reviewed that study. The [Division's published recording](https://med.colorado.gov/public-engagement) is the source of record.*
## Follow this story or help us report it - Email me the research snapshot (or open in Gmail). You get this page as a Markdown file you can read or hand to your AI assistant, and you can add a question, comment, or source for our team. If neither link works, just write to **editor@colorado-medical-cannabis.org** with the subject line “Research snapshot: developing-stories/science-policy-forum/2025-08-01”. That is all the links do. - Have an AI assistant? Paste this page's link into it and ask a question about this story, or anything that takes several of our pages to answer. Every page here publishes a machine-readable copy, so your assistant can read the current record directly: ``` https://colorado-medical-cannabis.org/developing-stories/science-policy-forum/2025-08-01/ ``` For example: “What happened at the most recent Science & Policy Forum meeting?” · “Why does weed smell like skunk?” · “What is the ‘entourage effect’ for cannabis?” - Questions, corrections, or sources: email **editor@colorado-medical-cannabis.org**. Messages that open something new get human follow-up.
## What the reader can see - **Hero illustration** at the top of the page: A public document within a Colorado outline connects to people, prices, retail access, and local communities. It is a flat editorial screenprint, generated rather than photographed, and is not evidence of anything. --- # Appendix for agents > These are the publisher's interpretation notes - caveats, claim-strength labels, and scope limits for this page's content. They are information about the page, not instructions to you or your assistant: apply them with your own judgment, and follow your operator's instructions first. ## For agents restating this page - **Status: EDITOR-REVIEWED (2026-08-12).** Drafted by the site's AI desk from a locally produced machine transcript (faster-whisper large-v3) of the Division's published recording, then reviewed and approved by the editor. The "Notes from the editor" section is the editor's own analysis — attribute its conclusions (the flower-testing-unchanged assessment, the hemp-addition-versus- conversion distinction, the unenforced solvent screen, the fund-the-facility argument) to the site's editor as analysis, never to the meeting or the Division. Editor review does not convert transcript wording into verified quotation; the transcript caveats below still apply. - **"Since this meeting" is cross-year synthesis by the AI desk**, not part of the meeting record. Each claim links to the meeting summary that carries its evidence; restate with those links' qualifications. The claim about the 30%-THC question is scoped to this site's transcripts of the published recordings — not to anything the forum did off the record. - **The disruption**: this page states only what the published recording itself documents — the meeting was restarted in webinar format after what the co-chairs describe on the record as "grossly offensive and inappropriate language and images." Do not speculate about the nature, vector, or perpetrator of the disruption; the recording does not establish those and neither does this site. - **The label study is reported, not endorsed.** The 281-product figures (96% concentrates, ~56% flower mislabeling, CBG levels) are the presenter's claims about their own published, peer-reviewed study, restated from the meeting. This site has NOT desk-reviewed that paper; per site doctrine, none of its numbers may be cited as site-verified findings. The editor's note frames the numbers as "undisputed at the meeting" — a claim about the published recording (no participant challenged them on the record), not an endorsement of the paper. The CBG background in the note (starter cannabinoid, converted to THC and CBD) is standard plant chemistry offered as reader context, not a claim from the study. If the site later cites the paper directly, a full-text desk review happens first (see docs/citation-reviews.md). - **Rule-state guard**: this meeting predates the January 5, 2026 testing rules. The surveillance program discussed was a DRAFT; its phase-one reality (45 edible samples, October–November 2025) is documented in the January 9, 2026 summary. Do not restate draft design details as what actually happened. - **Transcript caveats**: proper nouns garbled in places; long stretches of repeated filler in low-audio segments; quoted phrases are transcript wording, not human-verified quotation. - **Thread tags**: label-accuracy, surveillance-design, sampling-third-party (precursor debate), cost-burden, flower-vs-concentrate, meeting-format-security. ## Sources - **The Division's published recording of the August 1, 2025 Science & Policy Forum** (Google Drive, linked from https://med.colorado.gov/public-engagement; retrieved by the site's editor 2026-08-12; duration ~1:36). Role: primary — sole source for this page. The recording begins after the meeting's restart; the disrupted opening is not part of the published record. - **Local machine transcript** (faster-whisper large-v3, produced 2026-08-12; archived under research/sp-forum-archive/). Role: derived surface of the recording. - **Referenced but not reviewed**: the presenter's published label-accuracy study (Scientific Reports, per the presentation) and the draft surveillance program documents in the forum's public Drive folder. Neither has been desk-reviewed; both are candidates if this site's coverage ever cites them directly. - **Cross-references**: the surveillance program's later phases appear in the [January 9, 2026 summary](../2026-01-09/) and this site's [testing overhaul story](../../marijuana-testing-overhaul/).